A Pilot Study of Edoxaban in Patients with Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure

Inclusion Criteria: - The patient has documented paroxysmal, persistent, or permanent non-valvular AF (i.e., the patient has not been diagnosed with rheumatic mitral valve disease). - LAA closure with the WATCHMAN device is planned - The patient fulfills the FDA indication for WATCHMAN LAA closure - The patient or legal representative is able to understand and willing to provide written informed consent to participate in the trial - The patient is able and willing to return for required follow-up visits and examinations. - The patient is 18 years of age or older Exclusion Criteria: - Conditions other than atrial fibrillation that require anti-coagulation (e.g., a prosthetic heart valve) - Stroke within the previous 7 days - Hypersensitivity to edoxaban - Moderate or severe mitral stenosis - A need for aspirin at a dose of >81 mg a day - A need for on-going treatment with dual antiplatelet therapy with aspirin and clopidogrel - A need for on-going treatment with ticagrelor or prasugrel - No LAA closure device implanted during procedure - Procedural complication of LAA closure (e.g., stroke, systemic embolism, bleeding, vascular complication [e.g., groin hematoma >10cm, AV fistula, or pseudoaneurysm), or serious pericardial effusion) - Planned surgery or invasive procedure within 6±2 weeks of enrollment